Allergy & Immunology
Latest news
92 articles · 20 / page
Macrophage circHIPK2 Silencing Reduces Post-Infarction Inflammation and Fibrosis and Improves Cardiac Recovery
A 2026 European Heart Journal study identifies macrophage circHIPK2 as a regulator of post-MI inflammation and fibrosis, with macrophage-targeted silencing improving cardiac remodeling in mice and showing translational promise in human myoc
Cardiac Sarcoidosis May Be Driven by a Heart-Resident Autoimmune B-Cell Axis Linked to Periplakin
Single-cell and spatial transcriptomics suggest that cardiac sarcoidosis evolves through region-specific inflammatory programs and intracardiac B-cell autoimmunity, with periplakin emerging as a candidate autoantigen.
Colonic GPR15L Emerges as a Microbiota-Shaping Host-Defense Peptide That Protects Against Experimental Colitis
New data identify GPR15L as an epithelial host-defense peptide that reshapes the colonic microbiota, reduces experimental colitis, and may have therapeutic relevance in inflammatory bowel disease.
Twice-Yearly Depemokimab Maintained Asthma Control After Switching From Mepolizumab or Benralizumab, but Did Not Meet Formal Noninferiority for Exacerbations
In the phase 3A NIMBLE trial, switching biologic-responsive severe asthma patients to twice-yearly depemokimab preserved overall control and showed comparable safety, but formal noninferiority versus continued mepolizumab or benralizumab fo
Immune-Cell Transcriptomics and Mendelian Randomisation Identify New Causal Genes for Type 2 Diabetes Complications
This study used immune-cell gene expression and genetic analyses to identify causal genes and immune pathways linked to type 2 diabetes and its complications, highlighting diabetic neuropathy as a distinct cluster and prioritising ten promi
Oral Factor D Inhibition Falls Short in AChR-Positive Generalized Myasthenia Gravis: What the Vemircopan Phase 2 Trial Means for Complement-Targeted Therapy
In a phase 2 randomized trial, oral vemircopan did not improve clinical outcomes over placebo in AChR-antibody–positive generalized myasthenia gravis, despite a mechanistically attractive strategy to selectively inhibit the alternative comp
Five-Year Ublituximab Treatment Shows Sustained Benefits in Relapsing Multiple Sclerosis: ULTIMATE Extension Study
Long-term data from the ULTIMATE open-label extension study demonstrates sustained efficacy and safety of ublituximab in relapsing multiple sclerosis over five years, with significant reductions in relapse rates and disability progression c
Institutional Policy Shifts on Penicillin Allergy Labels Dramatically Increase Cefuroxime Use in Cataract Surgery
A large-scale quality improvement study reveals that reclassifying penicillin allergies and providing pharmacy support can increase the use of intracameral cefuroxime from 2% to over 70%, significantly improving evidence-based prophylaxis i
Sopoongsan Attenuates Chronic Pruritus via STAT1 Inhibition: Evidence from a Randomized Pilot Trial and Translational Models
A pilot randomized controlled trial and translational study demonstrate that Sopoongsan (SPS) effectively reduces chronic upper body pruritus in atopic and seborrheic dermatitis by inhibiting STAT1-mediated inflammatory pathways, offering a
Pumecitinib 3% Gel Shows Robust Efficacy and Minimal Systemic Absorption in Mild-to-Moderate Atopic Dermatitis Treatment
A Phase IIb clinical trial demonstrates that pumecitinib 3% gel significantly improves skin clearance in adults with mild-to-moderate atopic dermatitis. Twice-daily application proved superior to once-daily dosing, maintaining a favorable s
Beyond the Primary Endpoint: High-Dose Vilobelimab Demonstrates Clinical Utility in Reducing Draining Tunnels in Hidradenitis Suppurativa
The SHINE trial, despite missing its primary endpoint due to a high placebo response, suggests that high-dose vilobelimab significantly reduces draining tunnels in moderate-to-severe hidradenitis suppurativa, offering a potential new therap
Beyond Th2: Single-Dose Aletekitug Targets IL-18 to Deliver Sustained Clinical and Molecular Remission in Atopic Dermatitis
A phase 1/2 study reveals that a single dose of aletekitug, an anti-IL-18 antibody, provides durable clinical improvement and broad molecular modulation in moderate-to-severe atopic dermatitis, targeting pathways beyond traditional Type 2 i
Baricitinib Demonstrates Superior Efficacy Over Azathioprine in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Randomized Head-to-Head Trial
A randomized trial (NCT05969730) shows that baricitinib plus topical corticosteroids significantly outperformed azathioprine in achieving EASI 75 at 12 weeks (65% vs. 15%) in patients with moderate-to-severe atopic dermatitis, with both tre
Antenatal Prebiotic Supplementation Fails to Prevent Atopic Dermatitis in High-Risk Infants: Insights from the PREGRALL Trial
The multicenter PREGRALL trial demonstrates that maternal intake of galacto-oligosaccharide/inulin prebiotics from mid-gestation does not reduce the incidence of atopic dermatitis or allergic sensitization in high-risk infants by age one, c
Mapping Multimorbidity in Severe Asthma: Defining Replicable Phenotypes to Optimize Personalized Care
This review analyzes findings from the pan-European SHARP registry study, identifying distinct multimorbidity phenotypes in severe asthma. It highlights the impact of steroid-associated and sinonasal clusters on clinical outcomes, advocatin
Targeted HEV Modulation: A Novel Antibody-Drug Conjugate Strategy to Overcome Cardiac Allograft Rejection
Researchers have developed a first-in-class antibody-drug conjugate targeting High Endothelial Venules via the CHST4 enzyme. This therapy promotes regulatory T cell induction and long-term heart transplant survival in murine models using si
Bridging the Gap: A New Evidence-Based Patient Decision Aid for Systemic Atopic Dermatitis Therapy
Researchers have developed the first Patient Decision Aid (PDA) specifically for adult systemic atopic dermatitis treatments. The study highlights a ‘staged approach’ that balances clinician-driven data requirements with patient-preferred s
Beyond Antihistamines: Dupilumab Emerges as a Potent Strategy for Refractory Chronic Spontaneous Urticaria
The Phase 3 LIBERTY-CSU CUPID trials demonstrate that dupilumab significantly reduces itch and hives in patients with chronic spontaneous urticaria uncontrolled by antihistamines, providing a crucial new therapeutic option for those who are
Tezepelumab Enables Complete Oral Corticosteroid Discontinuation in 50% of Patients with Severe, Uncontrolled Asthma: Results from the WAYFINDER Phase 3b Trial
The WAYFINDER study reveals that tezepelumab significantly reduces OCS dependence in severe asthma, with over half of patients achieving complete discontinuation by week 52 while maintaining asthma control, regardless of baseline inflammato
Redefining Reliever Therapy: Budesonide-Formoterol Outperforms SABA in Controlling Airway Inflammation Among Patients on Maintenance Corticosteroids
The INFORM ASTHMA trial demonstrates that budesonide-formoterol as a reliever significantly reduces Type 2 airway inflammation (FeNO) compared to terbutaline in adults already using maintenance inhaled corticosteroids, establishing a new ev
Browse by specialty
Open language-specific specialty feeds and department pages.